Merck Says FDA Approves Keytruda for First-Line Treatment of Some Lung Cancer Patients
April 11 2019 - 05:37PM
Dow Jones News
By Stephen Nakrosis
Merck (MRK) on Thursday said the U.S. Food and Drug
Administration approved an expanded label for Keytruda as
monotherapy for the first-line treatment of certain patients with
stage III non-small cell lung cancer.
The approval is based on results from the Phase 3 KEYNOTE-042
trial, in which Keytruda monotherapy demonstrated a statistically
significant improvement in overall survival compared with
chemotherapy alone, the company said.
Keytruda works by increasing the ability of the body's immune
system to help detect and fight tumor cells, Merck said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 11, 2019 18:22 ET (22:22 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2023 to Mar 2024